Adjuvant incorporation in immunonanotherapeutics

A composition comprising:

• (1) synthetic nanocarriers having a size in the range of viral particles which are captured and retained on the surface of macrophages in the subcapsular sinus of draining lymph nodes,
• Wherein the nanocarrier comprises an immunofeature surface formed of an array of immobilized binding moieties, the array binding to dendritic or subcapsular sinus macrophages with high avidity and low affinity as compared to antibody binding;
• (2) an immunostimulatory agent, wherein the immunostimulatory agent is associated with the immunofeature surface, is associated with a second surface of the nanocarrier, or is encapsulated within the nanocarrier;
• (3) an MHC Class I, MHC Class II or CD1 presentable polypeptide, wherein the MHC Class I, MHC Class II or CD-1 presentable polypeptide is associated with the immunofeature surface, is associated with a second surface of the nanocarrier, or is encapsulated within a core region of the nanocarrier;
• and
• (4) a pharmaceutically acceptable excipient.